Synlogic (NASDAQ:SYBX) Stock Passes Above 50 Day Moving Average of $1.53

Synlogic, Inc. (NASDAQ:SYBX) shares passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.53 and traded as high as $1.57. Synlogic shares last traded at $1.51, with a volume of 2,797 shares trading hands.

Synlogic Price Performance

The stock has a market capitalization of $17.67 million, a PE ratio of -0.15 and a beta of 0.84. The stock’s fifty day moving average is $1.53 and its 200-day moving average is $1.63.

Synlogic (NASDAQ:SYBX) last posted its earnings results on Thursday, August 8th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.67. Synlogic had a negative net margin of 2,284.65% and a negative return on equity of 194.73%. On average, analysts forecast that Synlogic, Inc. will post -1.98 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Synlogic stock. Armistice Capital LLC increased its stake in Synlogic, Inc. (NASDAQ:SYBX) by 75.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,055,000 shares of the biotechnology company’s stock after acquiring an additional 455,126 shares during the quarter. Armistice Capital LLC owned approximately 11.48% of Synlogic worth $4,062,000 at the end of the most recent reporting period. Institutional investors own 63.40% of the company’s stock.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.